Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Completed · Phase 2

Conditions studied: Anxiety Disorders

In brief

This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Key facts

Study ID

NCT00108836

Run by

Novartis Pharmaceuticals

People needed

400

Starts

2005-03-01

Expected to finish

2006-05-01

Last updated by the study team

2010-05-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Current doctor's diagnosis of generalized anxiety disorder
• In need of psychiatric treatment
• Willingness to complete all aspects of the study

You may not qualify if…

• Current doctor's diagnosis of major depression
• History of schizophrenia or schizoaffective disorders
• Drug dependence within 2 months prior to study start
• For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:
• www.novartisclinicaltrials.com

Where it is running

• Investigational Site — Anaheim, California, United States
• Investigational Site — Los Angeles, California, United States
• Investigational Site — Newport Beach, California, United States
• Investigational Site — Redlands, California, United States
• Investigational Site — San Diego, California, United States
• Investigational Site — Fort Meyers, Florida, United States
• Investigational Site — St. Petersburg, Florida, United States
• Investigational Site — West Palm Beach, Florida, United States
• Investigational Site — Atlanta, Georgia, United States
• Investigational Site — Hoffman Estates, Illinois, United States
• Investigational Site — Oak Brook, Illinois, United States
• Investigational Site — Overland Park, Kansas, United States
• Investigational Site — Dayton, Ohio, United States
• Investigational Site — Portland, Oregon, United States
• Investigational Site — Madison, Tennessee, United States
• Investigational Site — Memphis, Tennessee, United States
• Investigational Site — Edmonton, Alberta, Canada
• Investigational Site — Kelowna, British Columbia, Canada
• Investigational Site — Hamilton, Ontario, Canada
• Investigational Site — Ottawa, Ontario, Canada
• Investigational Site — Toronto, Ontario, Canada
• Investigational Site — Montreal, Quebec, Canada
• Investigational Site — Sherbrooke, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.